Life Sciences

We create and invest in leading companies in therapeutics and medtech. If we can’t find a company solving an important problem, we create one ourselves — just like we did with Innovent, Denali, Beam, and Ultragenyx to name a few.

Life Sciences Portfolio

Spotlights Portfolio List People Impact

Portfolio List

Develops nausea treatments for surgical and cancer patients.
Acquired by Eagle Pharmaceuticals / EURONEXT: ACPH
Uses Smart Antibody Technology to accelerate development and reduce costs in antibody discovery.
NASDAQ: ADAG
Develops engineered T-cell therapies (TCR T-cells) to treat solid tumor and hematological cancers.
NASDAQ: ADAP
Develops protein conjugate therapies, combining biologics and small molecule payloads to treat cancer.
Develops targeted radioligand therapies (RLTs) to improve cancer treatment globally.
Develops precision medicines targeting protein synthesis for breakthrough cancer therapies.
Developing Amber-UI neuromodulation therapy using Picostim for urinary incontinence.
Develops alpha radioligand therapies (ARTs) for targeted cancer treatment with resilient supply chain.
Pioneering gene therapy company focused on transformative medicines for neurodegenerative disorders.
Developing innovative neuromodulation technology to treat large disease populations.
Develops and commercializes novel digital programmable hearing aid solutions for China.
Developing base editing technology for a range of applications.
Develops and commercializes high-quality hyaluronic acid (HA) based products for the Chinese market.
Rapidly growing pharmaceutical company focusing on emerging markets and expanding into regulated markets.
Employs DragonFold technology for rapid protein/ligand co-folding to develop novel drugs.
Develops and commercializes consumer healthcare and over-the-counter products.
Leader in discovery and development of novel drugs in stem cell related diseases.
Provides compact, affordable flow cytometry instruments with high multiplexing capabilities.
NASDAQ: CTBK
Specializing in biosimilars and novel biologics for global healthcare markets.
Developing cell and gene therapy manufacturing solutions for life sciences companies.
Developing innovative treatments for eye diseases and vision disorders.
SHA: 688050
Focused on affordable, high-quality medicines for patients worldwide.
Leveraging genomics data science to improve drug R&D and for population health.
Leading animal vaccine manufacturer in China.
603718.SS
Hemostatic product manufacturer in China.
Developing innovative drugs for diabetes and related metabolic disorders.
2552.KHK
Leading the change in cell & gene therapies & personalized immunotherapy.
Developing and commercializing high-quality biologic medicines.
1801.HK
Harnessing deep learning to accelerate pharmaceutical development.
Developing novel treatments for unmet medical needs.
Developing innovative therapies for autoimmune and inflammatory diseases.
NASDAQ: LSB
Research-driven pharmaceutical manufacturing organization.
NSE: LAURUSLABS
Develops and produces insulin pumps.
Developing nasal spray products to prevent respiratory viruses.
Manufactures, develops, and commercializes high quality, affordably priced cardiovascular and general surgery medical devices.
Bringing cell-based therapies to heart failure patients.
Manufactures and markets minimally invasive interventional therapy medical devices in the field of ENT, cardiovascular and others.
Developing small molecule inhibitors of the NLRP3 inflammasome.
Accelerating the advancement of globally competitive oncology assets for patients.
Developing treatments for rare diseases using bone-marrow gene therapy.
NASDAQ: ORTX
Promotes the development of cervical cancer screening and prevention in China.
Offers clean-label wellness supplements for health-conscious consumers through plant-based nutrition.
Developing and introducing effective and clinically proven children's medicines for China.
Designing novel therapeutics against previously undruggable targets using experimental and computational biophysics.
Developing and supplying plasma protein therapies for the treatment of rare and chronic diseases.
Developing inhaled therapies for severe respiratory infections and lung conditions.
Developing and commercializing therapies for rare diseases in Asia.
Providing quality medical equipment and supporting healthcare professionals and patients.
Developing gene therapies for retinal diseases causing blindness.
Developing therapies that target aging at the cellular level.
Pioneering novel immunotherapies for cancer treatment.
Facilitating data-driven life science research and empowering drug R&D processes.
Developing treatments for age-related degenerative diseases.
Developing innovative treatments for genetic diseases through gene therapy.
Developing oral therapies for chronic metabolic and cardiovascular diseases.
NASDAQ: GPCR
Advancing TCR bispecific therapies for cancer and autoimmune disorders.
Transforming global drug discovery with advanced AI and physics-based technologies.
Developing a novel therapy to treat presbyopia.
Developing diagnostic and imaging solutions for healthcare providers.
The companies identified do not represent all the companies purchased, sold, or recommended for portfolios advised by F-Prime. A full list of investments made by funds managed by F-Prime is available below.

People

Alex Pasteur, Ph.D.
Alexander Munoz, M.D.
Amber Cai, Ph.D.
Anastasiya Sybirna, Ph.D.
Bobby Gaspar, M.D., Ph.D.
Brian Yordy, Ph.D.
Carlos Bustamante, Ph.D.
Carolyn Haley, M.S., CPA
Catherine Stehman-Breen
Chong Xu, Ph.D.
Clare Bernard
Connie Li
Garth Rapeport
Harlan Krumholz, M.D.
Jessica Alston, Ph.D.
John Shiver, Ph.D.
Ketan Patel, M.D.
Kevin Chu
Martin Taylor, Ph.D.
Mike Feng
Muzammil Mansuri, Ph.D.
Natasha Rodgers, MB BChir
Nicholas Haining, BM, BCh
Nihal Sinha, MB BChir
Nikhil Ananth
Raj Basak, Ph.D.
Robert Weisskoff, Ph.D.
Stacie Weninger, Ph.D.
Stephen Knight, M.D.
Thomas Beck, M.D.

Impact